Description

• The popular medication lansoprazole, a second-generation proton pump inhibitor, is prescribed to treat ulcers.
• Release pattern in comparison to Prevacid solutab delayed-release oral disintegrating tablets and innovator Prevacid delayed-release capsules.
• Prevacid and Lansoprazole capsules from Murli Krishna Pharma were compared, and the results showed a favorable comparison in terms of solubility.
• The main goal of the MKPPL was to create a delayed release, durable, stable, and pharmaceutically comparable micropellet formulation of Lansoprazole for use in both capsule and orally disintegrating tablet form.
• Provide a full technical package for registrations in all markets that are regulated or partially regulated.